胆汁酸膜受体TGR5在胆道疾病中的研究进展

陈思平; 韩丽; 舒鹏; 代鑫; 程龙

doi:10.3969/j.issn.1001-5256.2022.03.047

胆汁酸膜受体TGR5在胆道疾病中的研究进展

DOI: 10.3969/j.issn.1001-5256.2022.03.047

陈思平^{1, 2},
韩丽^{1, 2},
舒鹏²,
代鑫²,
程龙^2, , ,

1.
西南交通大学医学院，成都 610031
2.
西部战区总医院全军普外中心，成都 610083

基金项目:

四川省青年科技基金 (2016JQ0023)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：陈思平负责课题设计，拟定写作思路并撰写论文；韩丽、舒鹏、代鑫参与收集数据，修改论文；程龙负责指导撰写文章并最后定稿。

详细信息

通信作者:
程龙，tmmulong@163.com

计量
- 文章访问数: 635
- HTML全文浏览量: 906
- PDF下载量: 105
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-21
- 录用日期: 2021-09-17
- 出版日期: 2022-03-20

Research advances in the bile acid membrane receptor TGR5 in biliary tract diseases

Siping CHEN^{1, 2},
Li HAN^{1, 2},
Peng SHU²,
Xin DAI²,
Long CHENG^{2
, ,
,}

1.
Southwest Jiaotong University College of Medicine, Chengdu 610031, China
2.
General Surgery Center of PLA, The General Hospital of Western Theater Command, Chengdu 610083, China

Research funding:

The Youth Foundation of Science and Technology Department of Sichuan Province (2016JQ0023)

More Information

Corresponding author: CHENG Long, tmmulong@163.com(ORCID: 0000-0002-0382-8212)

摘要

摘要: TGR5是一种胆汁酸激活的G蛋白偶联受体，在胆道系统生理及病理过程中发挥着重要作用。本文简述了在正常生理情况下，TGR5在肝脏及胆管中的正常表达情况，及发挥调节胆汁酸分泌、代谢，细胞保护作用等功能。归纳了在病理生理情况下，TGR5表达及功能的变化通过炎症反应、细胞增殖、凋亡等途径来影响疾病的发生与发展的机制。TGR5可能是未来治疗胆道疾病的潜在靶点。
- 胆道疾病 /
- 胆酸类 /
- 受体, G-蛋白偶联
Abstract: TGR5 is a bile acid-activated G protein-coupled receptor and plays an important role in the physiological and pathological processes of the biliary system. This article describes the normal expression of TGR5 in the liver and bile duct under normal physiological conditions and its functions including the regulation of bile acid secretion and metabolism and cytoprotection. This article also summarizes the changes in the expression and function of TGR5 under pathophysiological conditions and the mechanism of TGR5 in affecting the development and progression of biliary tract diseases through inflammatory response and cell proliferation and apoptosis. TGR5 may be a potential target for the treatment of biliary tract diseases in the future.
- Biliary Tract Diseases /
- Cholic Acids /
- Receptors, G-Protein-Coupled

HTML全文

图 1 TGR5相关通路示意图

下载: 全尺寸图片幻灯片

参考文献(41)

[1]	PERINO A, DEMAGNY H, VELAZQUEZ-VILLEGAS L, et al. Molecular physiology of bile acid signaling in health, disease, and aging[J]. Physiol Rev, 2021, 101(2): 683-731. DOI: 10.1152/physrev.00049.2019.
[2]	YANG F, MAO C, GUO L, et al. Structural basis of GPBAR activation and bile acid recognition[J]. Nature, 2020, 587(7834): 499-504. DOI: 10.1038/s41586-020-2569-1.
[3]	KEITEL V, REINEHR R, GATSIOS P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells[J]. Hepatology, 2007, 45(3): 695-704. DOI: 10.1002/hep.21458.
[4]	GUO C, CHEN WD, WANG YD. TGR5, Not only a metabolic regulator[J]. Front Physiol, 2016, 7: 646. DOI: 10.3389/fphys.2016.00646.
[5]	HOLTER MM, CHIRIKJIAN MK, BRIERE DA, et al. Compound 18 improves glucose tolerance in a hepatocyte TGR5-dependent manner in mice[J]. Nutrients, 2020, 12(7): 2124. DOI: 10.3390/nu12072124.
[6]	MASYUK AI, HUANG BQ, RADTKE BN, et al. Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 304(11): G1013-G1024. DOI: 10.1152/ajpgi.00383.2012.
[7]	NAKHI A, WONG HL, WELDY M, et al. Structural modifications that increase gut restriction of bile acid derivatives[J]. RSC Med Chem, 2021, 12(3): 394-405. DOI: 10.1039/d0md00425a.
[8]	VASSILEVA G, HU W, HOOS L, et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice[J]. J Endocrinol, 2010, 205(3): 225-232. DOI: 10.1677/JOE-10-0009.
[9]	WANG YD, CHEN WD, YU D, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice[J]. Hepatology, 2011, 54(4): 1421-1432. DOI: 10.1002/hep.24525.
[10]	BIAGIOLI M, MARCHIANÒ S, CARINO A, et al. Bile acids activated receptors in inflammatory bowel disease[J]. Cells, 2021, 10(6): 1281. DOI: 10.3390/cells10061281.
[11]	YANG H, ZHOU H, ZHUANG L, et al. Plasma membrane-bound G protein-coupled bile acid receptor attenuates liver ischemia/reperfusion injury via the inhibition of toll-like receptor 4 signaling in mice[J]. Liver Transpl, 2017, 23(1): 63-74. DOI: 10.1002/lt.24628.
[12]	GUO C, QI H, YU Y, et al. The G-Protein-Coupled Bile Acid Receptor Gpbar1 (TGR5) inhibits gastric inflammation through antagonizing NF-κB signaling pathway[J]. Front Pharmacol, 2015, 6: 287. DOI: 10.3389/fphar.2015.00287.
[13]	SU J, ZHANG Q, QI H, et al. The G-protein-coupled bile acid receptor Gpbar1 (TGR5) protects against renal inflammation and renal cancer cell proliferation and migration through antagonizing NF-κB and STAT3 signaling pathways[J]. Oncotarget, 2017, 8(33): 54378-54387. DOI: 10.18632/oncotarget.17533.
[14]	YANG H, LUO F, WEI Y, et al. TGR5 protects against cholestatic liver disease via suppressing the NF-κB pathway and activating the Nrf2/HO-1 pathway[J]. Ann Transl Med, 2021, 9(14): 1158. DOI: 10.21037/atm-21-2631.
[15]	ZHAO X, LI H, LYU S, et al. Single-cell transcriptomics reveals heterogeneous progression and EGFR activation in pancreatic adenosquamous carcinoma[J]. Int J Biol Sci, 2021, 17(10): 2590-2605. DOI: 10.7150/ijbs.58886.
[16]	REICH M, DEUTSCHMANN K, SOMMERFELD A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro[J]. Gut, 2016, 65(3): 487-501. DOI: 10.1136/gutjnl-2015-309458.
[17]	LIU X, CHEN B, YOU W, et al. The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2/STAT3 signaling pathway in non-small cell lung cancer[J]. Cancer Lett, 2018, 412: 194-207. DOI: 10.1016/j.canlet.2017.10.017.
[18]	PATHAK P, LIU H, BOEHME S, et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism[J]. J Biol Chem, 2017, 292(26): 11055-11069. DOI: 10.1074/jbc.M117.784322.
[19]	BIDAULT-JOURDAINNE V, MERLEN G, GLÉNISSON M, et al. TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload[J]. JHEP Rep, 2021, 3(2): 100214. DOI: 10.1016/j.jhepr.2020.100214.
[20]	PÉAN N, DOIGNON I, GARCIN I, et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice[J]. Hepatology, 2013, 58(4): 1451-1460. DOI: 10.1002/hep.26463.
[21]	DONEPUDI AC, BOEHME S, LI F, et al. G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice[J]. Hepatology, 2017, 65(3): 813-827. DOI: 10.1002/hep.28707.
[22]	KEITEL V, CUPISTI K, ULLMER C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders[J]. Hepatology, 2009, 50(3): 861-870. DOI: 10.1002/hep.23032.
[23]	KEITEL V, REICH M, HÄUSSINGER D. TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis?[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 218-225. DOI: 10.1007/s12016-014-8443-x.
[24]	LI T, HOLMSTROM SR, KIR S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling[J]. Mol Endocrinol, 2011, 25(6): 1066-1071. DOI: 10.1210/me.2010-0460.
[25]	SHI Y, SU W, ZHANG L, et al. TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation[J]. Front Immunol, 2020, 11: 609060. DOI: 10.3389/fimmu.2020.609060.
[26]	KANG JH, KIM M, YIM M. FXR/TGR5 mediates inflammasome activation and host resistance to bacterial infection[J]. Biochem Biophys Rep, 2021, 27: 101051. DOI: 10.1016/j.bbrep.2021.101051.
[27]	FRANKE A, BALSCHUN T, KARLSEN TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility[J]. Nat Genet, 2008, 40(11): 1319-1323. DOI: 10.1038/ng.221.
[28]	KARLSEN TH, FRANKE A, MELUM E, et al. Genome-wide association analysis in primary sclerosing cholangitis[J]. Gastroenterology, 2010, 138(3): 1102-1111. DOI: 10.1053/j.gastro.2009.11.046.
[29]	DEUTSCHMANN K, REICH M, KLINDT C, et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1319-1325. DOI: 10.1016/j.bbadis.2017.08.021.
[30]	REICH M, SPOMER L, KLINDT C, et al. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis[J]. J Hepatol, 2021, 75(3): 634-646. DOI: 10.1016/j.jhep.2021.03.029.
[31]	ZHANG R, MA WQ, FU MJ, et al. Overview of bile acid signaling in the cardiovascular system[J]. World J Clin Cases, 2021, 9(2): 308-320. DOI: 10.12998/wjcc.v9.i2.308.
[32]	FRYER RM, NG KJ, NODOP MAZUREK SG, et al. G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism[J]. J Pharmacol Exp Ther, 2014, 348(3): 421-431. DOI: 10.1124/jpet.113.210005.
[33]	YUSTA B, MATTHEWS D, FLOCK GB, et al. Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway[J]. Mol Metab, 2017, 6(6): 503-511. DOI: 10.1016/j.molmet.2017.03.006.
[34]	ERICE O, LABIANO I, ARBELAIZ A, et al. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1335-1344. DOI: 10.1016/j.bbadis.2017.08.016.
[35]	XU L, HAUSMANN M, DIETMAIER W, et al. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines[J]. BMC Cancer, 2010, 10: 302. DOI: 10.1186/1471-2407-10-302.
[36]	LAVOIE B, BALEMBA OB, GODFREY C, et al. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels[J]. J Physiol, 2010, 588(Pt 17): 3295-3305. DOI: 10.1113/jphysiol.2010.192146.
[37]	BRIERE DA, RUAN X, CHENG CC, et al. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice[J]. PLoS One, 2015, 10(8): e0136873. DOI: 10.1371/journal.pone.0136873.
[38]	VASSILEVA G, GOLOVKO A, MARKOWITZ L, et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation[J]. Biochem J, 2006, 398(3): 423-430. DOI: 10.1042/BJ20060537.
[39]	MASYUK TV, MASYUK AI, LORENZO PISARELLO M, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling[J]. Hepatology, 2017, 66(4): 1197-1218. DOI: 10.1002/hep.29284.
[40]	LARUSSO NF, MASYUK TV, HOGAN MC. Polycystic liver disease: The benefits of targeting cAMP[J]. Clin Gastroenterol Hepatol, 2016, 14(7): 1031-1034. DOI: 10.1016/j.cgh.2016.03.008.
[41]	SUSSMAN CR, WANG X, CHEBIB FT, et al. Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling[J]. Cell Signal, 2020, 72: 109649. DOI: 10.1016/j.cellsig.2020.109649.